Although the biological penetrance of amyloid and tau biomarkers with age in those studies was similar to our findings, the frequency of intermediate and high CERAD scores in our study is lower, and full penetrance of APOE4/4 for AD pathology with age was not observed as defined by the ADNC criteria. The gene discussed is MAPT; the disease is Alzheimer disease.